ZURICH: Roland Diggelmann said that the Roche acquired San Jose, the California-based Ariosa Diagnostics, Incorporate, a molecular diagnostics firm which makes a prenatal test to assess the risk of Down syndrome and other genetic abnormalities.
Roche diagnostics executive Roland Diggelmann said the acquisition of Ariosa is another example of Roche’s commitment to advanced molecular diagnostics. Financial details of the deal were not disclosed.
Further the Basel based drugmaker said in August it would buy US biotech company InterMune Inc for $8.3 billion in cash, in a move to expand into the treatment of rare or incurable diseases.
